Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
Vrachatis DA, Papathanasiou KA, Iliodromitis KE, Giotaki SG, Kossyvakis C, Raisakis K, Kaoukis A, Lambadiari V, Avramides D, Reimers B, Stefanini GG, Cleman M, Giannopoulos G, Lansky A, Deftereos SG. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs 2021, 81: 1381-1395. PMID: 34297330, DOI: 10.1007/s40265-021-01565-3.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Arrhythmia AgentsAtrial FibrillationAtrial RemodelingDiabetes Mellitus, Type 2Energy MetabolismHemodynamicsHumansInflammationMitochondriaSodium-Glucose Transporter 2 InhibitorsSympatholyticsUric AcidConceptsAtrial fibrillationSGLT2 inhibitorsCardiorenal protectionAntiarrhythmic effectsClinical dataSodium/glucose co-transporter-2 inhibitorClinical data implyDate available evidenceGlucose-lowering medicationsEffective therapeutic optionPotential pathophysiological linkLarge clinical trialsPre-specified endpointsType 2 diabetesPossible beneficial effectsPost Hoc AnalysisNormoglycemic adultsAF burdenAF preventionPathophysiologic mechanismsPathophysiological linkSGLT2 inhibitionAntiarrhythmic potentialSodium glucoseTherapeutic options